News - Anti-Arthritics/Rheumatics

Filter

Popular Filters

37 to 61 of 297 results

Horizon Pharma and Mundipharma in deal for Lodotra in Middle East and Africa

11-11-2013

USA-based Horizon Pharma has signed an exclusive agreement with privately-held Swiss drugmaker Mundipharma…

Anti-Arthritics/RheumaticsHorizon PharmaLicensingLodotraMundipharmaPharmaceuticalRest of the World

EMA Pharmacovigilance unit updates on Iclusig, diacerein and acipimox

EMA Pharmacovigilance unit updates on Iclusig, diacerein and acipimox

09-11-2013

At its November 4-7 meetings, the European Medicines Agency’s Pharmacovigilance Risk Assessment Committee…

acipimoxAnti-Arthritics/RheumaticsAriad PharmaceuticalsCardio-vasculardiacereinEuropeIclusigOncologyPharmaceuticalRegulation

Brazil’s MoH partners with Merck Serono to invest $430 million in bio-pharma production

Brazil’s MoH partners with Merck Serono to invest $430 million in bio-pharma production

08-11-2013

The Brazilian Ministry of Health is managing a series of product development partnerships and the selection…

Anti-Arthritics/RheumaticsBionovisBiotechnologyFinancialMerck KGaAMerck SeronoOncologyProductionSouth America

Positive new data on Bristol-Myers’s clazakizumab and nivolumab

Positive new data on Bristol-Myers’s clazakizumab and nivolumab

29-10-2013

US drug major Bristol-Myers Squibb and partner privately-held Alder Biopharmaceuticals have presented…

Alder BiopharmaceuticalsAnti-Arthritics/RheumaticsBristol-Myers SquibbclazakizumabnivolumabOncologyPharmaceuticalResearch

Roche and Chugai’s SC RoActemra improves RA long term

Roche and Chugai’s SC RoActemra improves RA long term

28-10-2013

Roche and its majority-owned Japanese subsidiary Chugai Pharmaceutical have announced that their RoActemra…

Anti-Arthritics/RheumaticsAsia-PacificChugai PharmaceuticalPharmaceuticalResearchRoActemraRoche

European prescribing attitudes for rheumatoid arthritis post-ADACTA

European prescribing attitudes for rheumatoid arthritis post-ADACTA

28-10-2013

Results from the ADACTA trial, which showed that Swiss drug major Roche’s RoActemra (tocilizumab) is…

AbbVieAnti-Arthritics/RheumaticsBiotechnologyEuropeHumiraMarkets & MarketingPfizerRoActemraRochetofactinib

Genentech’s SC Actemra approved by US FDA for severe RA

Genentech’s SC Actemra approved by US FDA for severe RA

22-10-2013

Genentech has announced that the US Food and Drug Administration has approved a subcutaneous formulation…

ActemraAnti-Arthritics/RheumaticsGenentechNorth AmericaPharmaceuticalRegulationRoche

US FDA approved auto-injector Otrexup from Antares Pharma for RA

US FDA approved auto-injector Otrexup from Antares Pharma for RA

15-10-2013

Antares Pharma has announced the approval of Otrexup (methotrexate) injection by the US Food and Drug…

Antares PharmaAnti-Arthritics/RheumaticsBiotechnologyNorth AmericaOtrexupRegulation

UCB’s Cimzia granted additional indication by US FDA

UCB’s Cimzia granted additional indication by US FDA

30-09-2013

UCB revealed today that the US Food and Drug Administration has approved its currently marketed drug…

Anti-Arthritics/RheumaticsCimziaNorth AmericaPharmaceuticalRegulationUCB

US FDA warns of hepatitis B reactivation risk with Arzerra and Rituxan

US FDA warns of hepatitis B reactivation risk with Arzerra and Rituxan

26-09-2013

The US Food and Drug Administration has approved changes to the prescribing information of the immune-suppressing…

Anti-Arthritics/RheumaticsArzerraBiogen IdecGlaxoSmithKlineNorth AmericaOncologyPharmaceuticalRegulationRituxanRoche

Inovio reveals success in DNA plasmid technology

Inovio reveals success in DNA plasmid technology

25-09-2013

US drug developer Inovio Pharmaceuticals has demonstrated the success of its new DNA plasmid technology…

Anti-Arthritics/RheumaticsBiotechnologyCNS DiseasesInovio PharmaceuticalsNorth AmericaOncologyResearch

Johnson & Johnson's Stelara gains FDA approval for psoriatic arthritis

24-09-2013

Janssen Research & Development announced that the US Food and Drug Administration has approved Stelara…

Anti-Arthritics/RheumaticsBiotechnologyJanssen BiotechNorth AmericaRegulationStelara Injection

Ablynx and AbbVie sign deal over rheumatoid arthritis nanobody

Ablynx and AbbVie sign deal over rheumatoid arthritis nanobody

23-09-2013

Belgian drug developer Ablynx and US drugmaker AbbVie have entered into a global license agreement to…

AbbVieAblynxAnti-Arthritics/RheumaticsEuropeLicensingPharmaceutical

Enbrel and Humira remain the mainstay for first-line biologic rheumatoid arthritis treatment in USA

19-09-2013

The vast majority of patients in the USA treated with Amgen's (Nasdaq: AMGN) Enbrel (etanercept) and…

AbbVieAmgenAnti-Arthritics/RheumaticsEnbrelHumiraMarkets & MarketingNorth AmericaPfizerPharmaceuticalXeljanz

EGA welcomes first biosimilar MAb approvals in Europe

12-09-2013

Following the European Medicines Agency's CHMP recommendation, the European Commission (EC) has just…

Anti-Arthritics/RheumaticsBiotechnologyGenericsPricingRegulation

First biosimilar monoclonal antibody approved in Europe

10-09-2013

US injectables and infusion technologies firm Hospira (NYSE: HSP) says the European Commission has approved…

Anti-Arthritics/RheumaticsBiotechnologyCellTrionEuropeGenericsHospiraInflectraMerck & CoRemicadeResearch

SOBI restructures Kineret and Kepivance deals

09-09-2013

Swedish Orphan Biovitrum (STO: SOBI) said this morning that it has acquired the full rights to develop…

AmgenAnti-Arthritics/RheumaticsBiotechnologyKepivanceKineretLicensingOncologyPharmaceuticalRare diseasesSwedish Orphan Biovitrum

Karo Bio gets first milestone in Pfizer collaboration

06-09-2013

Under its collaboration with US pharma behemoth Pfizer (NYSE: PFE), Sweden's Karo Bio (STO: KARO) says…

Anti-Arthritics/RheumaticsDermatologicalsFinancialKaro BioLicensingNeurologicalPfizerPharmaceuticalResearch

Baxter and Coherus in up to $246 million deal for biosimilar etanercept

04-09-2013

US companies Baxter International (NYSE:BAX) and Coherus Biosciences have entered into an exclusive collaboration…

AmgenAnti-Arthritics/RheumaticsBaxter InternationalBiotechnologyCoherus BioSciencesEnbreletanerceptGenericsLicensingResearch

EU approval for Ilaris in active systemic juvenile idiopathic arthritis

03-09-2013

Following a positive recommendation from the European Medicines Agency's Committee for Medicinal Products…

Anti-Arthritics/RheumaticsEuropeIlarisNovartisPharmaceuticalRegeneronRegulation

German pharma watch dog finds benefits for biologicals in RA

30-08-2013

The German Institute for Quality and Efficiency in Health Care (IQWiG) examined nine biotechnologically…

Anti-Arthritics/RheumaticsBiotechnologyCimziaEnbrelEuropeHumiraKineretMabTheraOrenciaPharmaceuticalPricingRegulationRemicadeRoActemraSimponi Injection

Phase III data support biosimilarity of BOW-015 to Remicade

29-08-2013

Privately-held US biotech firm EPIRUS Biopharmaceuticals, which is focused on the development and production…

Anti-Arthritics/RheumaticsBiotechnologyEPIRUS BiopharmaceuticalsGenericsinfliximabRegulationRemicadeResearch

Horizon Pharma in Duexis patent settlement

22-08-2013

Horizon Pharma (Nasdaq: HZNP) says it has entered into settlement and license agreements with Par Pharmaceutical…

Anti-Arthritics/RheumaticsDuexisGenericsHorizon PharmaNorth AmericaPar PharmaceuticalPatentsPharmaceutical

US FDA accepts Pennsaid 2% NDA for review

22-08-2013

The US Food and Drug Administration has accepted for filing US drugmaker Mallinckrodt's (NYSE: MNK) New…

Anti-Arthritics/RheumaticsGenericsMallinckrodtNorth AmericaNuvo ResearchPennsaidPharmaceuticalRegulation

37 to 61 of 297 results

Back to top